We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Genenta Science SPA (GNTA) ADS

Sell:$4.86 Buy:$5.00 Change: $0.26 (5.05%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$4.86
Buy:$5.00
Change: $0.26 (5.05%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$4.86
Buy:$5.00
Change: $0.26 (5.05%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including the United States.

Contact details

Address:
Via Olgettina 58
MILANO
20132
Italy
Telephone:
+ ()
Website:
www.genenta.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GNTA
ISIN:
US36870W1009
Market cap:
$91.26 million
Shares in issue:
36.58 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Pierluigi Paracchi
    Chairman of the Board, Chief Executive Officer
  • Richard Slansky
    Chief Financial Officer
  • Barbara Regonini
    Finance Director
  • Stefania Mazzoleni
    Scientific Project Manager and Communication Officer
  • Carlo Russo
    Chief Medical Officer, Head of Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.